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Abstract Background: The transcription factor sex determining region Y (SRY)-box 2
(SOX2) (3q26.3–q27) has been recently identiﬁed as a recurrently activated major oncogene
in squamous cell carcinoma of various sites. Its prognostic value in head and neck squamous
cell carcinoma (HNSCC) is currently unclear.
Aim: To correlate SOX2 protein expression with the occurrence of occult lymph node metas-
tasis and relapse free survival in early oral SCC.
Methods: SOX2 expression in 120 T1/T2 oral SCC patients was evaluated using a tissue
microarray technique. Intensity of SOX2 expression was quantiﬁed by assessing the Inten-
sity/Reactivity Scores (IRSs). These scores were correlated with the lymph node status of
biopsied sentinel lymph nodes and recurrence. Log rank univariate and Cox regression mul-
tivariate analysis was used to determine statistical signiﬁcance.
Results: Twenty-six of 120 primary tumours (21.7%) showed high SOX2 expression. High
expression levels of SOX2 signiﬁcantly correlated with negative lymph node status in univar-
iate (p = 0.001) and multivariate analysis (p = 0.003). Sensitivity was found to be 95.6% with a
negative predictive value of 92.3%. Speciﬁcity was 32% with a positive predictive value of
45.7%.
0959-8049/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejca.2013.01.005
⇑ Corresponding author: Tel.: +41 255 5860/5851.
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Conclusion: SOX2 up-regulation is frequent in early SCC of the oral cavity and associated
with decreased risk of lymphatic metastasis. SOX2 immunohistochemistry may be used as a
predictor for lymph node metastasis in squamous cell carcinoma of the oral cavity.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Head and neck squamous cell carcinoma (HNSCC)
is the ﬁfth-most common solid tumour diagnosed in
the world. The oral cavity is the most commonly
aﬀected subsite (274,000 cases) and ranks as the 12th
most common cancer.1 Advances in surgical and
radio-oncological management over the years have
unfortunately not signiﬁcantly improved oncological
outcomes for advanced cases, though ever more selec-
tive approaches to the neck and though innovative
ﬂap/reconstruction techniques have lowered morbidity
and improved function. Involvement of regional
lymph nodes at diagnosis roughly halves 5-year
survival.2
Several oncogenes have been identiﬁed in oral SCC.
Sex determining region Y (SRY)-box 2 (SOX2), a
transcription factor-coding gene located on 3q26.3–
27,3 has recently been shown to be frequently ampliﬁed
in SCCs of oesophagus and lung SCC.4,5 In oral squa-
mous cell carcinoma, SOX2 has also been reported to
be ampliﬁed and overexpressed.6 It encodes a tran-
scription factor involved in the determination of cell
fate and regulation of embryonic development. After
creating a protein complex with other proteins it acts
as a transcriptional activator that is essential to main-
tain self-renewal of undiﬀerentiated embryonic stem
cells.7–10 As forced Oct4 expression induces pluripoten-
cy in SOX2-null cells, a group of researchers have con-
cluded that the primary role of SOX2 in induced
pluripotent stem cells is controlling Oct4 expression,
and that they perpetuate their own expression when
expressed concurrently.11 Several recent publications
implicate a substantial role of SOX2 as prognostic fac-
tor for squamous cell carcinoma of various sites.
SOX2 ampliﬁcation was identiﬁed by FISH in 20–
23% of lung cancer; 11–15% of oesophagus cancer,
5–28 % of cervix SCC and 28% of skin cancer.4,5,12
In lung cancer, SOX2 overexpression is associated with
favourable prognosis, whereas the relevance of SOX2
expression for prognosis of HNSCC is controver-
sial.13–15
Sentinel node biopsy (SNB) of the N0 neck in early
oral SCC has been shown in several studies to reliably
detect occult neck metastasis with negative predictive
values >95%. To clarify a potential prognostic rele-
vance for occult metastasis of SOX2 protein expres-
sion, we consequently analysed a very well deﬁned
patient cohort with early oral SCC (T1/T2-stage)
undergoing sentinel lymph node biopsy.16,17
2. Patients and methods
Permission for performing the study was obtained
from the local ethics committee.
Detailed information of patient recruitment and sur-
gical procedure (including surgical resection of the pri-
mary tumour and SNB) can be found in former
articles by our group.18,19 In brief, 133 patients of the
ear nose and throat departments of the University Hos-
pital of Zurich and the Kantonsspital St. Gallen, Swit-
zerland, with early stage (T1/T2) SCC of the oral
cavity and the tonsillar pillar without preoperative clin-
ical and imaging evidence of regional lymph node metas-
tasis were selected for this study. SCCs of the tonsillar
pillar were included, because they behave similarly to
oral cavity carcinoma rather than Human Papilloma
Virus (HPV)-positive tonsillar carcinoma.20 Due to the
established fact, that a subgroup of oral and oropharyn-
geal SCC is caused by HPV infection,21 p16 immunohis-
tochemistry was used as a surrogate marker of HPV
status.22
For SNB, the radioactive tracer was injected preoper-
atively into the region of the primary tumour. Sentinel
lymph nodes (SLN) were intraoperatively located by
use of a gammaprobe, excised and subjected to immedi-
ate frozen section analysis. If occult metastases were
identiﬁed, a completion modiﬁed radical neck dissection
was performed in the same sitting.17 Patients whose
deﬁnitive histology showed a positive SNB underwent
interval neck dissection.
Formalin-ﬁxed, paraﬃn-embedded primary tumour
tissues of the 133 patients were histopathologically re-
evaluated. 13 patients were excluded from the analysis
because of loss of follow-up or inability to appropriately
evaluate the paraﬃn block. The mean clinical follow-up
of the remaining 120 patients (111 from Zurich, nine
from St. Gallen) was 81 months (range 11–122). Fig. 1
summarises the patients enrolled in this study (consort
diagram). Mean patient age was 59 years (range 28–
88). The tumour locations were in the oral cavity proper
(110/120 (91.7%); mostly tongue) and the palatine arch
(10/120 (8.3%)). Male:female ratio was 82:38 (2.16:1).
64 patients were staged pT1 and 56 pT2. Both sides of
the oral cavity were equally involved. 11% of tumours
were found in the midline. Table 2 gives a synopsis over
the clinical parameters.
For the construction of a tissue microarray (TMA) a
morphologically representative region of the “donor” -
paraﬃn blocks with primary tumour tissue was selected.
From this representative section two core biopsies
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(diameter, 0.6 mm; height, 3–4 mm) from the invading
front were taken and precisely arrayed into a new
“recipient” paraﬃn block using a custom-built instru-
ment.23 After the block production was ﬁnished, 4.0-
lm sections of the resulting tumour TMA block were
cut for further analysis as recently described.24,25
SOX2 immunohistochemistry was performed using
the rabbit monoclonal SOX2 antibody (1:100, Clone
EPR3131, Epitomics, Inc.) and a monoclonal mouse
anti-p16 antibody (clone JC8, 1:200, Santa Cruz Bio-
technology, Santa Cruz, CA, USA) on a Ventana
Benchmark automated staining system (Ventana Med-
ical Systems Inc., Tucson, AZ, USA) as recently
described.26 For SOX2, extranuclear staining was
regarded to be negative or unspeciﬁc. Immunohisto-
chemistry was evaluated in two cores per tumour.
The average percentage was taken for statistical analy-
sis. SOX2 staining intensity was measured by the Inten-
sity/Reactivity Score (IRS), which is frequently applied
for a detailed expression analysis of transcription fac-
tors. Staining intensity (SI) was assessed to be negative
(=0), weak (=1), moderate (=2) or strong staining
(=3). Reactivity (R) was determined by the percentage
of positive tumour cells (PP) and scored as follows:
negative (=0), 1–10% positive cells (=1), 11–30%
(=2), 31–50% (=3), 51–80% (=4) and >80% positive
cells (=5). IRS was calculated by multiplying PP with
SI (minimum 0/maximum 15). High expression was
deﬁned as P8 according to the median IRS of positive
stained cells.
According to recent literature,22 a strong and diﬀuse,
nuclear and cytoplasmic staining reaction of p16 in a
majority of tumour cells was considered as indicative
for an HPV-associated carcinoma.
2.1. Statistics
The relationship between presence of lymph node
metastasis and SOX2 expression was evaluated using
Fisher’s exact test. The predictive power of SOX2
expression for lymph node metastasis was evaluated
with a logistic regression controlling for grade of diﬀer-
entiation and tumour stage. Tumour diﬀerentiation was
not included as a factor in the logistic regression model
for the reason of “quasi” complete separation in the
data. In order to evaluate the potential of SOX2 as a
predictive marker for occult metastasis and eventually
for relapse time, a logistic regression and a Kaplan–
Meier survival analysis was performed. The possible
value of SOX2 expression as a predictive marker for
occult metastasis was additionally speciﬁed with calcula-
tion of sensitivity, speciﬁcity, positive and negative pre-
dictive values. How sensitivity and speciﬁcity were
calculated is illustrated in Table 1. Positive and negative
predictive values were calculated accordingly.
A Kaplan–Meier curve with calculation of log rank
statistics was performed to compare survival and relapse
rates, respectively, between patients with high and low
expression. PASW Statistics 18.0.0 for windows (SPSS)
was used for statistical analyses.
3. Results
SOX2 protein expression was virtually exclusively
identiﬁed in the nucleus of the tumour cells (Fig. 2).
Twenty-six of 120 (21.7%) of the primary tumours
showed a high SOX2 expression and 23/120 (19.2%)
were negative. For statistical analysis, tumours were
categorised according to the median value of stained
Fig. 1. Consort diagram of the patients included in the study. ITC = Isolated tumour cells/IRS = Intensity/Reactivity Score.
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positive cells into 3 categories: negative, low expressors
(IRS = 1–7) and high expressors (IRS = 8–15). These
groups were then compared to clinical course. There
was no association between SOX2 protein expression
and tumour diﬀerentiation grade or with tumour stage
(Table 2). High SOX2 expression correlated with nega-
tive lymph node status (p = 0.001) (Table 2, Fig. 3),
regardless of p16 state. After controlling for tumour
stage, SOX2 expression remained a signiﬁcant predictor
for lymph node status (odds ratio (OR) = 0.102, 95%
conﬁdence interval (CI): 0.023–0.457, p = 0.003;
Table 3).
SOX2 expression showed a sensitivity of 95.6% (95%
CI: 84.9–99.5%) and a speciﬁcity of 32.0% (95% CI:
21.7–43.8%) with regard to presence or absence of
lymph node metastasis. The positive predictive value
was 45.7% and the negative predictive value was 92.3%.
SOX2 expression was also evaluated for a possible
eﬀect on relapse rates. However, the log rank test did
not indicate any inﬂuence of SOX2 expression on
relapse rates. Gender, tumour location, side and T-stage
were not found to relate to occult metastasis.
3.1. p16 immunohistochemistry
Strong and diﬀuse, nuclear and cytoplasmic immuno-
histochemical p16 expression was detected in eleven of
120 tumours (9.2%). Ten of 110 tumours of the oral cav-
ity (9.1%) and one of ten oropharyngeal SCC (10%)
were p16-positive, suggesting an HPV-associated carci-
nogenesis. p16 could therefore be excluded as a relevant
confounder.
4. Discussion
In our study, we demonstrate that approximately
80% of early stage SCC of the oral cavity expresses
SOX2. High expression of SOX2 in these tumours is
associated with a signiﬁcantly lower incidence of occult
metastasis in neck lymph nodes.
Table 2
Association of SOX2 with tumour stage, diﬀerentiation and lymph node status.
SOX2 low (Intensity/Reactivity Score (IRS) 0–7) n = 94 (78.3%) SOX2 high (IRS 8–15) n = 26 (21.7%) p-Value
Tumour stage
pT1 48 (51.1%) 16 (61.5%) 0.381a
pT2 46 (48.9%) 10 (38.5%)
Diﬀerentiation grade*
Grade I (low) 13 (14.8%) 5 (20.8%) 0.360b
Grade II (moderate) 63 (71.6%) 17 (70.8%)
Grade III (high) 12 (13.6%) 2 (8.3%)
Sentinel node
Negative 51 (54.3%) 24 (92.3%) 0.001a
Positive 4 (5.7%) 2 (7.7%)
* Eight patients with diﬀerentiation grade not otherwise speciﬁed had to be excluded.
a Fisher’s exact test.
b Exact Mann–Whitney U test.
Table 1
Calculation of sensitivity and speciﬁcity depending on SOX2 expression (“2  2 table”).





New predictive marker for occult metastatic
disease (SOX2)




a b a + b
High SOX2
expression
c d c + d
All test
negatives
a + c b + d
All with occult disease All without occult
disease
Hypothesis: high SOX2 expression predicts absence of occult metastatic disease.
Sensitivity: c/(a + c).
Speciﬁcity: b/(b + d).
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The high SOX2 expression in early SCC of the oral
cavity is consistent with the hypothesis that SOX2 is
the target of chromosomal ampliﬁcations observed in
the 3q26-qter region by previous comparative genomic
hybridisation (CGH) studies. Copy number increases
of the 3q26-qter region have been identiﬁed in diﬀerent
SCCs, including lung, oesophagus and cervix.27–30 The
presence of frequent copy number gains/ampliﬁcations
suggested the presence of a relevant proto-oncogene in
this region.
SOX2 was ﬁrst reported to be ampliﬁed in SCCs of
oesophagus and lung,4,5 but also in SCC of the cervix
uteri, the skin and the penis.12
Freier et al.6 identiﬁed SOX2 as potential target of
the 3q gains/ampliﬁcations in HNSCC by array-CGH
and demonstrated high SOX2 protein expression in
about 18.1% (49/271) of oral SCC, using a polyclonal
rabbit anti-SOX2 antibody (Chemicon, Millipore,
MA). We observed a similar frequency of high SOX2
expression (21%) with a diﬀerent monoclonal antibody
(Epitomics).
Our result is consistent with a very high expression
level of nuclear SOX2 protein in the majority of primary
SCC, but high SOX2 expression has also been found in
breast cancer,31 testicular germ cell tumours,32 as well as
gastric33 and pancreatic adenocarcinoma.34 The mecha-
nisms for SOX2 protein overexpression are unclear.
SOX2 protein expression has also been reported in
tumours without gene ampliﬁcations.6,12 Interestingly,
SOX2 ampliﬁcations are obviously speciﬁc for SCC
Fig. 2. SOX2 immunohistochemistry of primary tumours: (a) absent expression, (b) low nuclear expression, (c) high nuclear expression.
Fig. 3. Sentinel status according SOX2 expression levels: While in none- and low expressors (Intensity/Reactivity Score (IRS) 0–7) sentinel node
negative patients overweigh sentinel node positive patients, in high expressors (8–15) most patients were found to be negative for occult metastatic
disease.
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pathogenesis, because adenocarcinomas of the lung or
cervix have no SOX2 ampliﬁcations,12 but high SOX2
protein expression.
In our well characterised cohort of early SCC of the
oral cavity, we were able to study the process of early
lymphatic metastasis and demonstrate a signiﬁcant asso-
ciation between high cancer cell-expressed SOX2 protein
and signiﬁcant lower risk of lymph node metastasis.
This result is consistent with ﬁndings in lung SCC,35
reporting high SOX2 protein expression levels and
SOX2 ampliﬁcation to be correlated with better overall
survival. The relationship between SOX2 expression and
tumour behaviour is highly controversial. It is intriguing
that there are some studies reporting increased aggres-
sive behaviour of tumour cells with SOX2 expression.
Du et al.13 showed a signiﬁcant association of high
SOX2 expression in nodal negative oral tongue carci-
noma with poor overall and disease-free survival using
the same interpretation method of the immunohisto-
chemical results, but a diﬀerent antibody (Novus Biolog-
icals). In their cohort of oral tongue SCC, 17.1% had a
high SOX2 score. There are diﬀerent explanations for
such controversial results:
(i) Diﬀerent results may be explained by the design of
retrospective studies. The problem of many studies
investigating predictive markers is the heterogene-
ity of primary tumours (location, T-stage and N-
stage), which are then analysed together. Since
patients qualifying for a sentinel node biopsy yield
a highly selected cohort (regarding tumour loca-
tion and N-stage) with no clinical evidence of
lymph node disease, we had the possibility to
detect cancers with occult metastatic disease at
the earliest time point.
(ii) Discrepancies could also be explained by the selec-
tion of tumours with diﬀerent pT stages. Our study
included only T1/T2 carcinoma, whereas Du et al.
also included T3 SCC (30% of the cases). The size
of their primary tumours correlated signiﬁcantly
with SOX2 expression. The multivariate analysis
by Du et al. showed that SOX2 as well as T-stage
were independent prognostic factors for unfavour-
able overall, cancer-speciﬁc and disease-free sur-
vival. Therefore, it remains unclear, which factor
(T-stage, lymph node metastasis or SOX2 expres-
sion) was most important for patients’ outcome.
(iii) A biological reason for a diﬀerent prognostic role
of SOX2 in diﬀerent tumour types could be the
involvement of additional oncogenes. In a meta-
phase comparative genomic hybridisation (CGH)
analysis, overrepresentation of the chromosomal
region 3q21-q29 was associated with decreased
overall and disease-free survival suggesting that
3q gains are involved in HNSCC progression.36
Several candidate proto-oncogenes are located
within this chromosomal arm, including PIK3CA
and CCNL1. Ampliﬁcation and protein expression
of PIK3CA37 and CCNL1 were reported in pri-
mary HNSCC38 and implicated in the progression
of HNSCC. CCNL1 ampliﬁcation was associated
with the presence of lymph node metastasis, but
the prevalence of this ampliﬁcation was relatively
low.
(iv) In a recent review by Hussenet et al.,39 a pleiotro-
pic oncogenic role of SOX2 in lung SCC was dis-
cussed: SOX2 overexpression seems to increase
the precursor basal cell and may be a triggering
event in the lung SCC pathogenesis. Furthermore
it seems, that SOX2 overexpression in cancer stem
cells (CSC) of lung SCC did not mediate self-
renewal like in CSC of glioblastoma, but leads to
more diﬀerentiated cancer cells. Finally the bind-
ing of SOX2 to diﬀerent co-factors and the activa-
tion of diﬀerent downstream targets can result in a
very diﬀerent aggressiveness of the tumour. It is
tempting to speculate that SOX2 has a similar
inﬂuence on tumour progression of HNSCC.
According to our data, SOX2 is a potential predictive
marker for a negative neck SLN in early SCC of the oral
cavity. Sentinel node biopsy has been successfully vali-
dated for early HNSCC. However, use of SNB alone or
SNB assisted elective neck dissection is still controver-
sially discussed for staging and treatment of the cN0 neck
in patients with early HNSCC. In addition, SNB is not
abundantly available and to date mostly reserved for ter-
tiary referral centres. The hitherto published predictive
factors for metastatic disease in SNB include histomor-
phological parameters of the primary tumour including
mode of invasion (morphological appearance of the inﬁl-
trating tumour front), grade of diﬀerentiation, lymphatic
invasion and intratumoural lymphatic density.40 In our
recent study,41 all these parameters failed to predict
metastasis in SNBof oral SCC. Therefore, additional bio-
markers may be of help for better patient stratiﬁcation to
select for SNB or elective neck dissection. In a previous
study, we demonstrated that expression of E-Cadherin
(ECAD)19 signiﬁcantly correlated with occult metastatic
disease. In the future, a combination of molecular
Table 3
Logistic regression: Adjusted odds ratios (ORs), 95% conﬁdence
intervals (95% CIs) and p-value of SOX2 expression and tumour stage
as predictors for lymph node status. Because of quasi-complete
separation in the data, diﬀerentiation grade was not included as a
factor in the logistic regression model.
Predictor OR 95% CI p-Value
SOX2 expression
High versus low 0.102 0.023–0.457 0.003
Tumour stage
pT2 versus pT1 1.665 0.758–3.659 0.204
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markers like SOX2, ECAD,19 podoplanin,18,25 p16, bmi-
1,42 Lysyl Oxidase (LOX)43 and histomorphologic
parameters may be used to stratify patients for the appro-
priate surgical lymph node procedure (SNB alone versus
SNB assisted elective neck dissection) according to their
risk for occult nodal disease. This would allow individual
risk stratiﬁcation with implications then for treatment
strategy.
In summary, we provide evidence that up-regulation
of cancer cell-expressed SOX2 correlates with lower inci-
dence of lymph node metastasis in early SCC of the oral
cavity. While SOX2 might not be applicable as a predic-
tive marker as a single test, SOX2 immunohistochemis-
try in combination with other molecular markers might
contribute to a more patient tailored treatment.
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Erläuterung zur Arbeit
Die Dissertantin begann ihre Arbeit unter der Leitung von PD Dr. med. Gerhard F. Huber im Juli 
2009. Es erfolgte in einem ersten Schritt ein ausgedehntes Literaturstudium zur Bestimmung der 
potentiell meistversprechendsten prädiktiven Marker der lymphogenen Metastasierung von p1 und 
p2 Karzinomen der Mundhöhle und des Oropharynx. Es wurden zunächst die Marker  E-Cadherin, 
p16, Cyclin D1 und EGFR, später  N-Cadherin, Periostin, Vimentin, Podoplanin sowie SOX-2 
studiert. Zu diesen erfolgte das Zusammenstellen der wichtigsten Informationen durch die 
Dissertantin zu Handen des Dissertationsbetreuers. 
Die zu untersuchende Kohorte umfasste 133 Patienten aus dem ORL-Departement des 
Universitätsspitals Zürich und neun aus dem ORL-Departement des Kantonspitals St. Gallen. Es 
erfolgte das zeitaufwändige Erstellen des Tissue Micro Array (nachfolgend TMA) in 
Zusammenarbeit mit der Klinischen Pathologie des Universitätsspitals Zürich. Bei einem TMA 
werden ausgestanzte Gewebezylinder in einen Paraffinblock eingebettet, geschnitten und 
angefärbt. Je nach Grösse dieser Gewebezylinder, den sogenannten Cores, können mit dieser 
Methode bis zu  1000 Proben von verschiedenen Patienten auf einem Objektträger gleichzeitig 
untersucht werden. Abhängig von der Dicke der Cores können von einem TMA bis zu 500 Schnitte 
gemacht und gefärbt werden.
Der  Dissertantin  oblag  es,  die  133 Patienten  anhand  ihrer  Patientennummer  im
Klinikinformationssystem zu identifizieren und die im Computersystem der  Klinischen Pathologie
hinterlegten Pathologieberichte zu studieren.  Im Falle der neun  Patienten   des Kantonssitals St.
Gallen organisierte sie die entsprechenden Tumorblöcke.  In einem zweiten Schritt  erfolgte das
Bestellen  der  nach Hämatoxylin-Eosin  gefärbten-Schnitte  (nachfolgend  HE-Schnitt) der
archivierten, in Paraffin eingebetteten 120 Tumor- sowie 10 Sentinellymphknotenresektate.  Die bei
einer  Operation  gewonnenen  Gewebeteile  werden  jeweils  einzeln  in  einen  Paraffinblock
eingebettet,  dies  bedeutet,  dass  von  den in  der  Kohorte  eingeschlossenen  Patienten  jeweils
mehrere  in  Paraffin  eingebettete  Tumorresektate vorhanden  sind.  Von  diesen  studierte die
Dissertantin jeweils den zugehörigen HE-Schnitt  und bestimmte  den für die TMA-Konstruktion
verwertbarsten  Tumorblock.  Die  bei  den  Operation  entnommen  Sentinel-Lymphknoten  wurden
ebenfalls  angefordert.  Danach  erfolgte  die  Identifizierung des  gewünschten Paraffinblockes im
Archiv und eine erneute Anfertigung eines HE-Schnittes. Auf diesem zeichnete die Dissertantin
unter  dem Mikroskop die  beste stanzbare Region im Tumor ein.  Ziel  war  es,  auf  dem später
entnommenen  Core  nur  Anteile  der invasiven  Tumorfront ohne  Verhornungen  oder  normalen
Gewebes zu haben. Im Falle der Sentinel-Lymphknoten erfolgte die Beurteilung, ob es quantitativ
genug Tumormaterial für eine Core-Entnahme  vorhanden ist.   Um eine hohe Aussagekraft des
TMA  gewährleisten  zu  können,  wurde  jede  von  der  Dissertantin  ausgewählte  Region  in
Zusammenarbeit  mit  einem Pathologen  nochmals verifiziert  und  gegebenenfalls  ein  anderer
Tumorblock ausgewählt und neu eingezeichnet.
Anhand des HE-Schnittes als Orientierungshilfe wurde aus dem Paraffinblock mit Tumorgewebe
(„Spender“)  ein Gewebezylinder entnommen und dieser sorgfältig in einen neuen Paraffinblock
(„Empfänger“)  eingefügt.  Um  den  Nachteil  auszumerzen,  dass  der  ausgestanzte
Gewebeausschnitt  nicht  repräsentativ  für  das  gesamte  Gewebe  sein  könnte,  wurden je  zwei
Cores  pro Patient  genommen.  Bei  teilweise sehr  kleinen Tumormassen erfolgte  dies  in  enger
Zusammenarbeit  der Dissertantin mit  der Leiterin des TMA-Labors, um eine hohe Qualität  des
TMA gewährleisten zu können. Es wurde für den TMA einen Stanzendurchmesser von 0.6 mm und
eine Höhe von 3-4 mm gewählt. Nachdem der „Empfänger“Paraffinblock mit Cores  der  Patienten
bestückt  worden  war,  wurde  der  Block  in  4.0µm  dünne  Scheiben  geschnitten,  deparaffiniert,
rehydriert und mit den primären Anitkörpern inkubiert. Die Färbung wurde mit dem automatischen
Ventana Benchmark Färbesystem erstellt. Diese Arbeit erfolgte durch das TMA-Labor. 
Jeder einzelne Core wurde von der Dissertantin und dem Dissertationsbetreuer mit dem virtuellen
Mikroskop des Universitätsspitals  Zürich analysiert  und nach dem Immunreactivity Score (IRS)
bewertet. Der IRS ist eine Skala zur Quantifizierung der immunhistochemischen Anfärbung, die
durch das Multiplizieren der Anteile der angefärbten Zelle mit der Färbeintensität entsteht.  Da pro
Patient zwei Cores gefärbt wurde, wurde durch die Dissertantin jeweils der Durchschnitt der IRSs
berechnet und für die weiteren statistischen Analysen verwendet.  
Zuerst erfolgte die immunhistochemische Auswertung der pro Färbung insgesamt 262 Cores von
E-Cadherin,  p16,  Cyclin  D1  und  EGFR,  nachfolgend  die  Analyse  von   N-Cadherin,  Periostin,
Vimentin, Podoplanin sowie später SOX-2 in Zusammenarbeit mit Dr. med. M. Roessle. 
Für die klinische Korrelation oblag es der Dissertantin, im Klinikinformationssystem die Daten des
Follow  ups der  Patienten  zusammenzustellen.  13  Patienten  mussten  schlussendlich  wegen
fehlendem Follow up oder  nicht  auswertbarem TMA ausgeschlossen werden.  Der  IRS wurden
dann mit dem Status der  Senitellymphknoten sowie der Rezidivrate korreliert. Die statistischen
Signifikanz  wurde  durch  den  Log-Rank-Test  sowie  durch  das  Regressionsmodell  nach  Cox
ermittelt. 
Daraus erfolgten die Publikationen „Down regulation of E-Cadherin (ECAD) - a predictor for occult
metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity
and oropharynx“,  „Podoplanin expression correlates with sentinel lymph node metastasis in early
squamous cell carcinomas of the oral cavity and oropharynx“ jeweils mit der Erstautorenschaft von
PD Dr. med. G. Huber, sowie auf deren Grundlage „EGFR expression and copy number changes
in low T-stage oral squamous cell carcinomas“ von Dr. med. M. Roessle. Die Publikation „High sex
determining region Y-box 2 expression is a negative predictor of occult lymph node metastasis in
early squamous cell carcinomas of the oral cavity“ wird nun als geteilte Erstautorenschaft von Dr.
med. M. Rössle und der Dissertantin angeführt.  
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